Brokers Issue Forecasts for CVS Health FY2026 Earnings

CVS Health Co. (NYSE:CVS) – Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for CVS Health in a report released on Monday, June 9th. Cantor Fitzgerald analyst S. James forecasts that the pharmacy operator will post earnings per share of $6.82 for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for CVS Health’s current full-year earnings is $5.89 per share.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to analyst estimates of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. CVS Health’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the business posted $1.31 earnings per share.

A number of other analysts also recently issued reports on CVS. Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Cowen reaffirmed a “buy” rating on shares of CVS Health in a report on Monday, May 5th. Truist Financial lifted their price target on CVS Health from $82.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, May 12th. Piper Sandler lifted their price target on CVS Health from $72.00 to $74.00 and gave the stock an “overweight” rating in a report on Friday, March 21st. Finally, UBS Group boosted their target price on CVS Health from $67.00 to $71.00 and gave the company a “neutral” rating in a report on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $74.75.

CVS Health Stock Up 2.3%

Shares of NYSE CVS opened at $65.71 on Tuesday. The company has a market capitalization of $83.12 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 0.98 and a beta of 0.56. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The business has a 50-day moving average of $65.11 and a two-hundred day moving average of $60.05. CVS Health has a 1 year low of $43.56 and a 1 year high of $72.51.

Hedge Funds Weigh In On CVS Health

Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in CVS Health during the 4th quarter worth approximately $839,574,000. Capital World Investors increased its position in CVS Health by 26.6% during the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator’s stock worth $2,739,927,000 after purchasing an additional 12,819,148 shares during the period. Davis Selected Advisers increased its position in CVS Health by 2,998.1% during the 4th quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator’s stock worth $511,115,000 after purchasing an additional 11,018,438 shares during the period. Dodge & Cox increased its position in CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator’s stock worth $3,147,054,000 after purchasing an additional 7,075,209 shares during the period. Finally, Pzena Investment Management LLC increased its position in CVS Health by 49.3% during the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator’s stock worth $880,319,000 after purchasing an additional 6,475,271 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity at CVS Health

In related news, Director Guy P. Sansone purchased 1,570 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The shares were purchased at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the transaction, the director now directly owns 12,007 shares of the company’s stock, valued at approximately $764,845.90. The trade was a 15.04% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.22% of the stock is currently owned by insiders.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were given a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 4.05%. The ex-dividend date of this dividend was Tuesday, April 22nd. CVS Health’s dividend payout ratio (DPR) is presently 63.48%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.